Pharmaceuticals

Suzhou GenAssist Therapeutic Co.,Ltd recently announced that its first base editing product, GEN6050, has submitted a pre-IND application to the FDA and has been accepted

SUZHOU, China, May 6, 2023 /PRNewswire/ -- Suzhou GenAssist Therapeutic Co.,Ltd recently announced its pre-IND application of their first base editing product, GEN6050 and the acceptance by the FDA.   GEN6050 is an in vivo base editing drug that targets exon 50 skipping in the Duchenne muscular...

2023-05-06 21:00 4602

Empowering Innovation to the Global Market with Acro Certify

NEWARK, Del., May 5, 2023 /PRNewswire/ -- For many companies, entering the global market is a daunting challenge. These obstacles can come in various forms. Sometimes the problem is finding the right target customer base or establishing an appropriate quality management system and shipping logist...

2023-05-06 10:18 4752

Empowering Innovation to the Global Market with Acro Certify

TOKYO, May 6, 2023 /PRNewswire/ -- For many companies, entering the global market is a daunting challenge. It is an immense logistical and financial challenge that makes or breaks a company, despite the product itself. For companies in that awkward, transitional stage from start-up company to a m...

2023-05-06 10:18 4256

CARsgen's CLDN18.2 mAb AB011 Achieves IND Clearance from the NMPA for the First-line Combination Treatment of Gastric Cancer

SHANGHAI, May 5, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced that AB011 in combination with atezolizumab monoclonal antibody, Roche'...

2023-05-05 20:50 3158

Viva Biotech's Recent Conferences & Events Review

HONG KONG, May 5, 2023 /PRNewswire/ -- In April, Viva Biotech was invited to attend 2022 SAPA-China Annual Conference, 88th API China, Drug Discovery Chemistry, American Association for Cancer Research (AACR) Annual Meeting 2023, CPHI Japan 2023, PharmFuture 2023 Small Molecule Innovative Drug Fu...

2023-05-05 19:58 3730

ProQure and Identiv Partner to Launch Innovative NFC Type 2 Tags for Large-Scale NFC Deployments

The partnership's new PQ201/201s series tags deliver premium features at a competitive price point PLEASANTON, Calif., May 5, 2023 /PRNewswire/ -- ProQure, a technology provider of IoT cloud management for physical objects, and Identiv, a global leader in physical security and secure identificat...

2023-05-05 18:00 2258

P&G Health commemorates Neuropathy Awareness Week 2023 with an effort to help people 'Put Life Back in Their Hands'

* Dons the purple ribbon for the 2nd consecutive year to raise awareness on Peripheral Neuropathy, a condition significantly underdiagnosed and undertreated inAsia, Middle East & Africa * Releases new research study highlighting the role of B Vitamins in supporting healthy nerve functions SIN...

2023-05-05 11:30 3373

Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery

TAIPEI, May 4, 2023 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (6838.TWO) and AimMax Therapeutics, Inc. (United States) announce the submission of a New Drug Application to the United States Food & Drug Administration (US FDA) for APP13007, a novel aqueous nanosuspension formulation of the pot...

2023-05-05 08:00 1774

Recall Notice - SD Biosensor, Inc. requests discontinuation of use and disposal of specific Pilot™ COVID-19 At-Home Tests in the United States due to microbial contamination in the liquid buffer solution

SEOUL, South Korea, May 4, 2023 /PRNewswire/ -- SD Biosensor, Inc. today is requesting that consumers stop using and dispose of specific Pilot COVID-19 At-Home Tests inthe United States because potentially harmful bacteria were found in the tube with liquid inside (pouch 2 of the kits). The affe...

2023-05-05 04:00 2022

ABM Announces First Patient Dosed in Phase I Clinical Trial of MEK Inhibitor for Solid Tumor

SAN DIEGO and SHANGHAI, May 4, 2023 /PRNewswire/ -- ABM Therapeutics, an innovative clinical-stage biopharmaceutical company, with an emphasis on developing drugs with high blood–brain barrier (BBB) penetration for CNS diseases including brain metastases, today announced that the first patient wa...

2023-05-05 01:00 2303

SNIPR Biome's data on first clinical drug candidate to prevent infections in hematological cancer patients published in Nature Biotechnology

* SNIPR001 is a novel CRISPR-Cas therapeutic designed to selectively target antibiotic resistantE. coli, which can cause fatal infections in vulnerable hematological cancer patients             * SNIPR001 represents the first CRISPR- therapeutic developed to specifically removeE. coli in the ...

2023-05-05 00:52 2560

ANGUS ANNOUNCES CORPORATE REBRANDING, WILL CHANGE NAME TO "ADVANCION"

New name and brand reflect Company's strategic transformation into a leading global producer of specialty ingredients for Life Sciences, Personal Care and other essential markets BUFFALO GROVE, Ill., May 4, 2023 /PRNewswire/ -- ANGUS Chemical Company ("ANGUS" or "Company") today unveiled a new n...

2023-05-04 21:00 3285

First Subject Enrolled in Boan Biotech's International Multi-Center Phase 3 Clinical Study for Its Denosumab BA6101 & BA1102

YANTAI, China, May 4, 2023 /PRNewswire/ -- Boan Biotech today announced that an international multi-center Phase 3 clinical study for its in-house developed Denosumab Injection (BA6101; BA1102) has been initiated inEurope, the United States, and Japan, and recently the first patient in (FPI) was ...

2023-05-04 14:40 3635

Hasten Biopharma Acquires Commercial Rights in China for Roche's Antibiotic Rocephin®

The acquisition will deliver strong commercial synergy with Hasten's current critical care portfolio SHANGHAI, May 4, 2023 /PRNewswire/ -- Hasten Biopharmaceutic Co., Ltd (China) ("Hasten") today announced that it has acquired the commercial rights inChina for Rocephin®, a long-acting, broad spe...

2023-05-04 14:00 1817

SHL Medical and MoonLake Immunotherapeutics collaborate to develop sonelokimab autoinjector

ZUG, Switerland, May 3, 2023 /PRNewswire/ -- SHL Medical, a world-leading provider of advanced drug delivery solutions, announced that it has signed a collaboration agreement with MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for infl...

2023-05-03 22:43 2502

EDAN Announces Integration with PointClickCare for Better Senior Primary Care

SAN DIEGO, May 3, 2023 /PRNewswire/ -- Edan Instruments, Inc. (300206.SZ), a leading healthcare company and medical devices manufacturer, recently announced its integration with PointClickCare through its newly launched informatics solutions Allink. The solution ...

2023-05-03 21:56 2059

Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial

BELTSVILLE, Md., May 3, 2023 /PRNewswire/ -- Reprocell USA, a CRO, has been awarded a contract to provide support for Lantern Pharma's Phase 2 clinical trial entitled "A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma (HARMONIC)". The Harmonic™ s...

2023-05-03 21:00 2017

Skyline Therapeutics to Present at the ASGCT 26th Annual Meeting

SHANGHAI, May 3, 2023 /PRNewswire/ -- Skyline Therapeutics, an innovation-driven gene therapy company dedicated to developing unique and novel solutions to address unmet needs in rare and severe diseases, today announced multiple data presentations at the American Society of Gene and Cell Therapy...

2023-05-03 12:00 1741

Chula Researchers Develop Rapid MTB Strip Test for Tuberculosis

Lecturers of the Faculty of Allied Health Sciences, Chulalongkorn University have developed the MTB Strip Test Kit for Tuberculosis (TB) diagnosis that's accurate and easy to use, guaranteed by the 2023 Invention Award from the National Research Council of Thailand (NRCT) -- Another hope to reduce...

2023-05-03 11:34 2994

Merck Signs MoU with Ministry of Trade, Industry & Energy and Daejeon City for New Asia Pacific BioProcessing Production Center in South Korea

* MoU with Merck's Life Science business aimed at supporting the region's healthcare ecosystem * Proposed bioprocessing facility to be based in Daejeon City * Further collaboration aims to support emerging biotech companies and academic research DAEJEON CITY, South Korea, May 3, 2023 /PRNe...

2023-05-03 10:00 3087
1 ... 67686970717273 ... 294